SNSE - Sensei Biotherapeutics, Inc. Stock Price, Fair Value and News

$0.45+0.02 (+4.65%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SNSE Price Action

Last 7 days

2.3%

Last 30 days

-10%

Last 90 days

-16.7%

Trailing 12 Months

-28.6%

SNSE RSI Chart

SNSE Valuation

Market Cap

11.3M

Price/Earnings (Trailing)

-0.38

Price/Sales (Trailing)

3.97

Price/Free Cashflow

-0.45

SNSE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SNSE Fundamentals

SNSE Revenue

Revenue (TTM)

2.9M

Rev. Growth (Yr)

-32.61%

Rev. Growth (Qtr)

-11.66%

SNSE Earnings

Earnings (TTM)

-29.8M

Earnings Growth (Yr)

-1.81%

Earnings Growth (Qtr)

-1.55%

SNSE Profitability

Return on Equity

-65.1%

Return on Assets

-55.96%

Free Cashflow Yield

-222.54%

SNSE Investor Care

Shares Dilution (1Y)

0.62%

Diluted EPS (TTM)

-1.19

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.4M	3.1M	2.9M	0
2023	2.4M	3.0M	3.4M	3.6M
2022	1.0M	1.3M	1.5M	1.8M
2021	0	0	0	800.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

CEO	Mr. John K. Celebi M.B.A., MBA
WEBSITE	senseibio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	23

Sensei Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Sensei Biotherapeutics, Inc.? What does SNSE stand for in stocks?

SNSE is the stock ticker symbol of Sensei Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sensei Biotherapeutics, Inc. (SNSE)?

As of Fri Dec 20 2024, market cap of Sensei Biotherapeutics, Inc. is 11.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNSE stock?

You can check SNSE's fair value in chart for subscribers.

Is Sensei Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNSE is over valued or under valued. Whether Sensei Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact Sensei Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNSE.

What is Sensei Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, SNSE's PE ratio (Price to Earnings) is -0.38 and Price to Sales (PS) ratio is 3.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNSE PE ratio will change depending on the future growth rate expectations of investors.